This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Changes in Mitochondrial Uncoupling Protein 2 (UCP2) Messenger RNA(mRNA) in Type 2 Diabetes (T2DM) Patients (Diabetes)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2013 by Tel-Aviv Sourasky Medical Center.
Recruitment status was:  Recruiting
Sponsor:
Information provided by (Responsible Party):
Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:
NCT01781754
First received: January 8, 2013
Last updated: January 30, 2013
Last verified: January 2013
January 8, 2013
January 30, 2013
January 2013
January 2014   (Final data collection date for primary outcome measure)
Levels of gene expression for UCP2 (RQ) [ Time Frame: 6 months ]
Checking UCP2 levels compared to HgBA1c
Same as current
No Changes Posted
Improved metabolic state [ Time Frame: 6 months ]
Glycemic control (glucose level and HgA1c), levels of free reactive oxygen species (ROS) and non-esterified fatty acids (NEFAs).
Same as current
Not Provided
Not Provided
 
Changes in Mitochondrial Uncoupling Protein 2 (UCP2) Messenger RNA(mRNA) in Type 2 Diabetes (T2DM) Patients
Changes in UCP2 mRNA in T2DM Patients

Many patients with Diabetes find difficulties in achieving glycemic control. Hemoglobin A1c(HgBA1c) is used as a marker for glycemic control. UCP2 is affected by high glucose levels, high free fatty acids and high oxidative stress.

The investigators intend to learn about the changes in UCP2 along the process of reaching glycemic control.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
Whole blood for UCP2 mRNA
Non-Probability Sample
Un balanced diabetic patients
Diabetes
Procedure: Blood withdrawal
This is the only intervention that is part of the study. A family physician or other physician will be responsible of the diabetic treatment (common treatment, e.g Metformin).
Diabetic patients
Un balanced diabetic patients
Intervention: Procedure: Blood withdrawal

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
50
January 2014
January 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Un balanced diabetic patients.

Exclusion Criteria:

  • No current infection.
Sexes Eligible for Study: All
20 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
 
NCT01781754
TASMC-11-NV-561-CTIL
No
Not Provided
Not Provided
Tel-Aviv Sourasky Medical Center
Tel-Aviv Sourasky Medical Center
Not Provided
Not Provided
Tel-Aviv Sourasky Medical Center
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP